Skip to content
Menu

JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.

JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.

Read at benzinga.com

← All stock news